STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Ecnoglutide

Also known as

XW003 · XW-003 · Sciwind ecnoglutide · cAMP-biased GLP-1 · ecnoglutide injection

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic Subcutaneous weekly Metabolic / GLP-1 class

Systemic weekly GLP-1 shot — whole-body appetite, not a site pin.

What people say Ecnoglutide, also called XW003, is Sciwind’s cAMP-biased GLP-1 receptor agonist, approved in China for type 2 diabetes and weight management as a once-weekly subcutaneous product. It is distinct from semaglutide, tirzepatide, retatrutide and mazdutide. Doses people talk about
Type 2 diabetes trial arms0.6 and 1.2 mg weekly

EECOH-1 tested these weekly ecnoglutide arms against placebo.

Obesity SLIMMER trial arms1.2, 1.8 and 2.4 mg weekly

Sponsor tables report distinct week-40 and week-48 weight outcomes; these are trial arms, not a community chart.

No US label or settled gray-market amount is established; the rows report study arms rather than a use progression. US gray-market evidence gap: No settled community band. A vial bearing the development code does not establish Sciwind product identity or a validated amount.

Half-life & effect duration

Half-life in the body
  • Repeated weekly use · studyAbout 124–138 hours — roughly 5–6 days
Felt duration people report
  • Felt durationNo consistent firsthand ecnoglutide window reported
Timing context & sources
How it may feel The inspected English-language community sources discussed trial news, competition and expected GLP-1 side effects rather than verified first-person ecnoglutide use. A product-specific felt timeline is therefore not established.
Cycles people discuss The development model is weekly, long-term metabolic treatment, not an eight-week cycle. Trial duration and maintenance do not establish a community schedule for unverified products. Timing In the Phase 1 multiple-dose cohorts, ecnoglutide’s steady-state half-life was 124–138 hours. This supports weekly development but does not provide a measured duration for appetite suppression, nausea or other felt effects. Around the dose Clock: Weekly, same weekday, like sema/tirz habits — if someone actually has it. Stacks Ecnoglutide was studied alone in the preserved trial framing. English-language community stack discussion remains theoretical rather than a verified product-specific practice. Access talk Not a 503A compounding staple in US boards the way sema/tirz were. Watch for Thin US identity. A vial labeled XW003 is not automatically Sciwind.
Related
SemaglutideTirzepatideRetatrutideMazdutideOrforglipron

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Steady-state ecnoglutide half-life was 124–138 hours in the Phase 1 multiple-dose cohorts.

Healthy participants received 0.2–0.6 mg subcutaneously once weekly for six weeks after single-dose cohorts spanning 0.03–1.0 mg.

Small early-phase healthy-participant pharmacokinetics do not establish long-term outcomes, gray-product identity or a subjective-effect duration.

Felt duration people report

A product-specific felt-duration window is not established in the inspected English-language community material.

The inspected Reddit thread discussed Phase 3 news, potential competition, cost and expected class side effects rather than verified first-person ecnoglutide use.

General GLP-1 expectations and sponsor adverse-event tables cannot substitute for a first-person onset-and-duration account; gray product identity is also unverified.

Other context in this card

  • Sciwind Biosciences draft application proof (opens in a new tab)Printed pp.169–170 (PDF pp.177–178): SLIMMER 1.2, 1.8 and 2.4 mg weekly arms, week-40 primary and week-48 secondary outcomes, 48 weeks of treatment and 7 weeks of safety follow-up. Printed pp.174–175 (PDF pp.182–183): January 2026 T2D and March 2026 obesity approvals in China. EECOH-1 tables list 0.6 and 1.2 mg weekly diabetes arms.Sponsor-prepared listing document, not an independent head-to-head trial or a US prescribing label; estimands and timepoints must remain explicit.

What people say 4

  • Biased-agonist folklore: “More appetite, less nausea” is the hope; GI still shows up in GLP-1s. forum
  • What talk does not prove: A US gray-market vial that matches Sciwind’s product. Human n=1 English logs are thin. forum
  • Weight-loss trial bands in the mid-teens percent at ~6–8 months — GLP-1-class, not reta-class headlines. trial
  • Glucose / HbA1c in China T2D Phase 3 (0.6 and 1.2 mg weekly vs placebo). trial

Doses people talk about 4

  • US gray milligrams: Not a settled community band as of 2026-09. forum
  • T2D trial weekly: 0.6 mg and 1.2 mg in EECOH-1. trial
  • Obesity SLIMMER weekly: 1.2 / 1.8 / 2.4 mg. Week-40 means around −9 / −11 / −13%; week-48 2.4 mg ~−15% in company tables. trial
  • Framing: Trial milligrams — not a US label, not a research-chem chart everyone agrees on. forum

How it may feel 3

  • Honest thinness: Public English n=1s are not a reta-style Reddit corpus. Expect GLP-1-class nausea/food-noise stories if people get a real vial. forum
  • Weeks 1–4: Standard GLP titration nausea/fatigue in the class. forum
  • If you feel nothing: Product identity is the first suspicion on a name this new in the US gray market. forum

Around the dose 2

  • Clock: Weekly, same weekday, like sema/tirz habits — if someone actually has it. forum
  • Protein / lifting: Same muscle-loss anxiety as every GLP thread. forum

Cycles people discuss 2

  • Not an 8-week blast. forum
  • Weekly trial treatment: SLIMMER studied 48 weeks of treatment followed by 7 weeks of safety follow-up; this is a specified trial course, not open-ended treatment. trial

Timing 2

  • Class GI timing: worst after a dose jump, then quieter for some. forum
  • Weekly pin is the development clock. trial

More on what it is 5

  • What most people mean: A China-approved weekly GLP-1 that US peptide Twitter treats as a pipeline name, not a fridge staple. forum
  • Why it is thin on this map: 2026 US diaries are sparse. Mazdutide/reta/orforglipron steal the English-language oxygen. China T2D and weight-management approvals are the news. forumtrial
  • Not: Not semaglutide, not tirzepatide, not retatrutide, not mazdutide. forum
  • What it is: Sciwind’s cAMP-biased GLP-1 analogue (XW003). Favors cAMP signaling over β-arrestin in the marketing. Peptide. trial
  • Numbers people paste: SLIMMER-type obesity talk ~13.2% weight loss at 40 weeks on 2.4 mg; Phase 2 up to ~14.7% at 26 weeks. EECOH-1 T2D HbA1c drops vs placebo at 0.6/1.2 mg weekly. trial

Stacks 2

  • US stack talk is theoretical — people still on sema/tirz/reta. forum
  • Solo GLP in trials. trial

Access talk 3

  • Not a 503A compounding staple in US boards the way sema/tirz were. forum
  • Gray-market name should be treated as thin and possibly fake. forum
  • China approvals 2026 for diabetes and chronic weight management talk; no US FDA story yet. trial

Storage notes 2

  • China/trial pens vs gray lyophilized powder is the identity problem. forum
  • Fridge lore follows other GLP vials if reconstituted. forum

Watch for 4

  • GLP-1 GI class: nausea, constipation, fullness. trialforum
  • Thin US identity. A vial labeled XW003 is not automatically Sciwind. forum
  • Gallbladder / lean-mass / rebound class worries copy-pasted from sema threads. forum
  • Not FDA-approved in the US as of this card. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →